Dalpiciclib combined with endocrine therapy for patients with HR+/HER2− metastatic breast cancer: a multicenter real-world study
Therapeutic Advances in Medical Oncology
Published online on July 29, 2026
Abstract
Therapeutic Advances in Medical Oncology, Volume 18, January-December 2026.
Background:Dalpiciclib is the latest cyclin-dependent kinase 4/6 (CDK4/6) inhibitor approved in China. Real-world data regarding the efficacy and safety of dalpiciclib for metastatic breast cancer (MBC) are still insufficient.Objectives:This study aims to ...
Background:Dalpiciclib is the latest cyclin-dependent kinase 4/6 (CDK4/6) inhibitor approved in China. Real-world data regarding the efficacy and safety of dalpiciclib for metastatic breast cancer (MBC) are still insufficient.Objectives:This study aims to ...